Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,417
datasets available to search
ShareScore release 0.9.0
Dataset results
1,417 results for “triple negative breast cancer”
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
ClinicalTrials.gov study NCT06732323. IPD Sharing: NO. Countries: 1. Publications: 0.
Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment
ClinicalTrials.gov study NCT05435352. IPD Sharing: NO. Countries: 1. Publications: 0.
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
ClinicalTrials.gov study NCT05111561. IPD Sharing: YES. Countries: 1. Publications: 0.
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer
ClinicalTrials.gov study NCT06910072. IPD Sharing: NO. Countries: 1. Publications: 0.
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
ClinicalTrials.gov study NCT04243616. IPD Sharing: NO. Countries: 1. Publications: 0.
A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer
ClinicalTrials.gov study NCT04914390. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
ClinicalTrials.gov study NCT03356860. IPD Sharing: NO. Countries: 1. Publications: 0.
Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT07139470. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT04134884. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients
ClinicalTrials.gov study NCT06825975. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)
ClinicalTrials.gov study NCT06246786. IPD Sharing: YES. Countries: 1. Publications: 0.
[18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers
ClinicalTrials.gov study NCT04320030. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT04149444. IPD Sharing: NO. Countries: 1. Publications: 0.
Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
ClinicalTrials.gov study NCT05910710. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
ClinicalTrials.gov study NCT06606730. IPD Sharing: NO. Countries: 2. Publications: 0.
Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel
ClinicalTrials.gov study NCT05582538. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer
ClinicalTrials.gov study NCT05134194. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02897050. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer
ClinicalTrials.gov study NCT06365788. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01698281. IPD Sharing: Not stated. Countries: 2. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.